Adagene Inc - ADR
ADAG
|
$2.65
620
|
Manufacturing
(0.0% 1d) (3.5% 1m) (103.8% 1y) (0.0% 2d) (-2.9% 3d) (0.4% 7d) (482.81% volume)
Earnings Calendar:
Market Cap: $ 116,909,178
https://www.adagene.com
Sec Filling | Patents | 2020 employees
(China (Mainland)) Adagene Inc. is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational biology and artificial intelligence to design novel antibodies that address unmet patient needs. Its proprietary pipeline is comprised of novel immunotherapy programs. Adagene has forged strategic collaborations with reputable global partners that leverage its technology in multiple approaches at the vanguard of science.
cancer immunotherapy antibody computational
add to watch list Paper trade email alert is off
Press-releases
Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update
Published: 2024-03-29 (Crawled : 13:00) - globenewswire.com
SNY | News | $46.765 -1.94% 950K
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $94.25 480
|
Health Technology
| Email alert
Add to watchlist
ADAG | $2.65 620
|
Manufacturing
| Email alert
Add to watchlist
year update financial results
Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board
Published: 2024-03-07 (Crawled : 21:00) - globenewswire.com
ADAG | $2.65 620
|
Manufacturing
|
| O: -1.4%
H: 5.69%
C: 0.36%
Adagene to Present at the Leerink Partners Global Biopharma Conference 2024
Published: 2024-02-27 (Crawled : 13:00) - globenewswire.com
ADAG | $2.65 620
|
Manufacturing
|
| O: -2.37%
H: 6.06%
C: -0.61%
conference biopharma global
Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)
Published: 2024-02-09 (Crawled : 11:00) - globenewswire.com
ADAG | $2.65 620
|
Manufacturing
|
| O: -1.43%
H: 10.14%
C: 6.67%
adg126 safebody cancer expansion collaboration program
Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)
Published: 2024-01-16 (Crawled : 22:00) - globenewswire.com
ADAG | $2.65 620
|
Manufacturing
|
| O: -12.17%
H: 20.78%
C: 20.48%
adg126 safebody cancer results
Adagene To Present Interim Results of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at ASCO-GI Symposium
Published: 2024-01-04 (Crawled : 10:00) - globenewswire.com
ADAG | $2.65 620
|
Manufacturing
|
| O: 2.59%
H: 5.05%
C: -3.67%
adg126 safebody symposium results
Adagene Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 at SITC 2023
Published: 2023-11-03 (Crawled : 16:00) - globenewswire.com
ADAG | $2.65 620
|
Manufacturing
|
| O: -1.61%
H: 1.5%
C: 1.5%
adg126 safebody index
Adagene Announces Poster Presentation on Optimal Dose Selection for Masked Anti-CTLA-4 SAFEbody® ADG126 at Upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
Published: 2023-10-12 (Crawled : 12:00) - globenewswire.com
ADAG | $2.65 620
|
Manufacturing
|
| O: 3.36%
H: 0.0%
C: -9.09%
adg126 safebody presentation cancer immunotherapy meeting
Adagene to Present at Investor and Scientific Conferences in September
Published: 2023-09-07 (Crawled : 10:00) - globenewswire.com
ADAG | $2.65 620
|
Manufacturing
|
| O: -4.06%
H: 10.77%
C: 7.69%
MS | News 0 d | $93.88 0.13% 2.7M
|
Finance
|
| O: -0.12%
H: 0.0%
C: 0.0%
Adagene to Present at Investor and Scientific Conferences in September 2023
Published: 2023-09-07 (Crawled : 11:00) - biospace.com/
ADAG | $2.65 620
|
Manufacturing
|
| O: -4.06%
H: 10.77%
C: 7.69%
MS | News 0 d | $93.88 0.13% 2.7M
|
Finance
|
| O: -0.12%
H: 0.0%
C: 0.0%
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 58% | 42% |
Top 10 Gainers
CSSE 4 | $0.3831 151.54% 190M
|
Consumer Services
CZOO | $11.04 121.24% 11M
|
LICN | $0.9107 62.63% 14M
|
BOF | $1.87 59.83% 100M
|
AMST | $3.18 59.0% 67M
|
Technology Services
MTC | $3.31 47.77% 7.7M
|
Technology Services
MULN | News | $3.915 43.41% 12M
|
Information
WIMI | $1.04 43.37% 17M
|
Technology Services
SKIL 4 | $8.045 40.89% 230K
|
Information
RILY | $30.01 38.17% 11M
|
Finance
Last 48 Hours Insiders Buying
WABC | $47.5 -0.54% 24K
|
Finance
|
19:30
NWFL | News | $24.0 -0.46% 4.9K
|
Finance
|
17:00
MNSB P 310 | $15.82 -3.3% 21K
|
Finance
|
15:30
TPL P 3 | $584.82 -0.51% 20K
|
Miscellaneous
|
15:01
ISBA P 966 | $18.0001 3.1K
|
Finance and Insurance
|
15:01
MEGI | $12.05 0.58% 120K
|
|
00:30
CTRN P 29000 | $21.95 -1.26% 33K
|
Retail Trade
|
22:00
CONN | $3.74 1.08% 27K
|
Retail Trade
|
21:30
TGEN P 6000 | $0.685 6.6K
|
Utilities
|
18:30
CMTV P 700 | $16.59 1K
|
Finance and Insurance
|
18:30
FNB | $13.595 -0.26% 1.1M
|
Finance
|
17:30
RMCF | $3.54 7.1K
|
Consumer Non-Durables
|
20:10